

Editorial

# The Journal of Respiratory Biology and Translational Medicine, a Versatile Platform for Basic and Clinical Science

Jeffrey A. Whitsett<sup>1,\*</sup> and Jianwen Que<sup>2,\*</sup>

<sup>1</sup> Perinatal Institute, Divisions of Neonatology, Perinatal and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

<sup>2</sup> Department of Medicine, Division of Digestive and Liver Diseases, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA

\* Corresponding author. E-mail: jeffrey.whitsett@cchmc.org (J.A.W.); jq2240@cumc.columbia.edu (J.Q.)

Received: 21 November 2023; Accepted: 21 November 2023; Available online: 21 November 2023



© 2024 by the authors; licensee SCIEPublish, SCISCAN co. Ltd. This article is an open access article distributed under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

We are delighted to introduce you to *The Journal of Respiratory Biology and Translational Medicine* (JRBTM), an official journal of Chinese American Lung Association (CALA). JRBTM is an open access, high-quality medical journal with a focus on both basic and clinical aspects of lung biology.

Acute and chronic lung diseases are major causes of morbidity and mortality affecting individuals throughout the life course and throughout the world. In spite of recent remarkable scientific advances in cell and molecular biology, there remains pressing needs for the prevention, diagnosis, and treatment of life-threatening lung diseases. Advances in genetics and cell biology are providing evermore clarity regarding the genes and cellular mechanisms underlying the pathogenesis of acute and chronic lung diseases, lung cancer, and the mechanisms involved in the normal regeneration of pulmonary tissues. Single cell biology is beginning to identify cell-cell interactions on the signaling and transcriptional processes controlling lung formation, injury, remodeling, and repair. *In vivo* and *ex-vivo* models create evermore powerful experimental platforms to identify and test normal repair and disease mechanisms. Progresses in comprehending the identities, intrinsic properties, and niche regulations of stem/progenitor cells offer a fresh perspective on lung development, the initiation and progression of pulmonary diseases, and potential treatments. Advances in our understanding of the impact of our rapidly changing environment and accompanying exposures beginning *in utero* and continuing throughout life on pulmonary health, provide new opportunities to prevent pulmonary disease. Together, these advances highlight compelling opportunities to understand and treat pulmonary disorders. *The Journal of Respiratory Biology and Translational Medicine* provides a new platform to explore the intersection of gene and environmental exposure, genetics, cell and molecular biology, seeking to understand disease pathogenesis to prevent and treat pulmonary disorders affecting individuals worldwide.

*The Journal of Respiratory Biology and Translational Medicine* aims to provide a high-end international platform for medical and basic research scientists to showcase their innovative thoughts, groundbreaking scientific findings, and state-of-the-art technologies. The journal will publish the most updated scientific information from fundamental, clinical, and translational research on lung development, regeneration and diseases.

The scope of *The Journal of Respiratory Biology and Translational Medicine* encompasses all the subspecialties relevant to basic biology, physiology, and pathophysiology of lung and lung diseases. Related topics include but are not limited to lung molecular and cellular biology, development, physiology and biophysics, genetics, genomics, immunology, experimental therapeutics, pharmacology, clinical trials, aging health, health policy, and epidemiology. The journal welcomes submissions of manuscripts in the forms of original research articles, research protocols, methodology papers, clinical reports, clinical commentaries, case study reports, clinical guidelines, short communications, correspondence, and review articles.

*The Journal of Respiratory Biology and Translational Medicine* is committed to providing fast, fair, and expert peer-review to authors. Once accepted, the journal will rapidly make the content available to readers. The journal selected its editorial team and editorial board members from an international pool of outstanding researchers and clinicians who have gained high levels of professional recognition and achievement in the lung field. We value veracity above all other virtues. Our editorial team agrees that a highest-standard and rigorous peer-review process is necessary for achieving the goal of the journal presenting the best of science to our audience. We have set up reliable mechanisms for assessing the quality and veracity of submissions. Our editorial team, along with all other editorial personnel, will strive with enthusiasm to make *The Journal of Respiratory Biology and Translational Medicine* a world-class forum for lung basic and medical sciences.

*The Journal of Respiratory Biology and Translational Medicine* is scheduled to launch its first issue in March 2024. This journal, based in Hong Kong, is fully open to the global scientific community. We welcome you to join us as editorial board members, reviewers, or contributors.